加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.00
−US$0.13 · -11.50%
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
前收盘价
US$1.00
−US$0.13 · -11.50%
盘后
US$1.01
+US$0.01 · +1.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
日内区间
当前US$1.00
52周区间
当前US$1.00
盘中时间采用ET。市场数据可能有所延迟。
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
日内区间
当前US$1.00
52周区间
当前US$1.00
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 83.2万 USD | — | — | — | — |
| 毛利 | −83.2万 USD | — | — | — | — |
| 研究与开发 | 740.7万 USD | 450.4万 USD | 236.8万 USD | 114.7万 USD | 52.1万 USD |
| 销售、一般及管理费用 | 924.2万 USD | 923.3万 USD | 652.1万 USD | 332万 USD | 105.7万 USD |
| 营业费用 | 1581.7万 USD | 1373.7万 USD | 888.9万 USD | 446.7万 USD | 157.8万 USD |
| 利息收入 | 24.7万 USD | 25.1万 USD | — | — | — |
| 利息支出 | 20.4万 USD | 2万 USD | 14.7万 USD | 65.4万 USD | 4000 USD |
| 折旧和摊销 | 83.2万 USD | 57.3万 USD | 43.7万 USD | 9.4万 USD | — |
| 营业利润 | −1664.9万 USD | −1373.7万 USD | −888.9万 USD | −446.7万 USD | −157.8万 USD |
| 净利润 | −1864.6万 USD | −1116.1万 USD | −1648.5万 USD | −512.1万 USD | −158.2万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
